Diving into Data Trends and Ongoing Research in Advanced Endometrial Cancer - Episode 2

LEAP-001 Data for First-Line Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer

,

Christian Marth, MD, PhD, and John Chan, MD, discuss data for frontline lenvatinib plus pembrolizumab in advanced endometrial cancer.